サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1634208

アブレーションデバイスの世界市場 - 2025年～2033年

Global Ablation Devices Market - 2025 - 2033

出版日
ページ情報
英文 159 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
アブレーションデバイスの世界市場 - 2025年～2033年
出版日: 2025年01月13日
発行: DataM Intelligence
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アブレーションデバイスの世界市場は、2024年に62億米ドルに達し、2033年には141億米ドルに達し、予測期間2025年～2033年にはCAGR 9.7%で成長すると予測されています。

アブレーションデバイスは、様々な治療手順で使用される特殊な医療器具であり、標的エネルギーによって異常組織や疾患組織を除去、破壊、治療します。これらの器具は低侵襲処置で使用されることが多く、周囲の健康な組織へのダメージを最小限に抑えながら、精密で制御された治療方法を提供します。アブレーションは通常、熱、冷、電気、光などさまざまな形態のエネルギーを用いて行われます。アブレーションデバイスは現代医療において重要な役割を担っており、様々な病状に対して、より安全で、効率的で、侵襲の少ない治療法を患者に提供しています。

アブレーションデバイス市場は、アブレーションデバイスの進歩、製品発売の増加、低侵襲治療への嗜好の高まりにより、大きな成長を遂げています。例えば、アボット社は2024年10月、電気生理学におけるパルスフィールドアブレーション（PFA）ソリューションの拡大を支える新たな主要マイルストーンを達成しました。Volt PFAシステムをサポートするVOLT-AF IDE試験の早期登録完了と、発作性心房細動患者の治療に使用される同社のTactiFlex Duoアブレーションカテーテル、センサーイネーブルド（SE）を評価するFOCALFLEX試験の開始です。

市場力学：

促進要因と抑制要因

アブレーションデバイスにおける技術進歩の高まり

アブレーションデバイスにおける技術進歩の高まりは、アブレーションデバイス市場の成長を大きく後押ししており、予測期間中も市場を牽引すると予測されます。特に画像診断システムやガイダンスシステムの技術進歩により、アブレーション処置の精度が大幅に向上しています。これらの技術革新は、適用範囲を広げ、処置時間を短縮し、患者の転帰を改善し、低侵襲な選択肢へのアクセスを拡大しています。

高度な電気解剖学的マッピングシステムの統合は、心臓病学、特に心房細動の治療における使用に革命をもたらしました。心臓の電気的活動を正確にマッピングできるようになったことで、治療後の成功率が向上し、不整脈の再発も少なくなった。

例えば、2024年10月、ボストン・サイエンティフィック社は、発作性心房細動（AF）治療用のナビゲーション機能付きアブレーションカテーテルFARAWAVE NAVの米国食品医薬品局（FDA）承認と、FARAPULSEパルスフィールドアブレーション（PFA）システムと組み合わせて心臓アブレーション手技の視覚化を提供する新しいFARAVIEWソフトウェアのFDA 510（k）クリアランスを取得しました。

さらに、2024年10月、メドトロニックは、持続性心房細動（AFib）の治療および心房粗動のCTI依存性心房粗動（CTI）のRFアブレーション用のオールインワンの高密度（HD）マッピング、パルスフィールド（PF）および高周波（RF）アブレーションカテーテルであるスフィア-9カテーテル付きアフェラマッピング・アブレーションシステムの米国食品医薬品局（FDA）承認を発表しました。

ロボット支援アブレーションシステムは、手技の精度とコントロールを向上させています。例えば、2024年12月、Stereotaxis Inc.と中国のパートナーであるShanghai Microport EP Medtech Co.Ltd.は、中国で薬剤抵抗性の不整脈を治療するためにStereotaxisのロボットアブレーションシステムと併用するMagbot磁気ナビゲーションアブレーションカテーテルの国家医療製品管理局（National Medical Products Administration）の承認を得た。

起こりうる副作用と合併症

アブレーション治療に伴う潜在的な副作用や合併症は、アブレーションデバイス市場の成長にとって重要な課題です。こうしたリスクは患者やヘルスケアプロバイダーにアブレーション技術の採用を躊躇させ、その普及を制限する可能性があります。例えば、心房細動に対するラジオ波焼灼術や冷凍焼灼術では、食道の損傷や呼吸困難などの合併症を引き起こす可能性があります。

カテーテルを用いたアブレーションのような侵襲的治療には、挿入部位の感染や出血のリスクがあります。例えば、肝腫瘍に対するマイクロ波焼灼術（MWA）やラジオ波焼灼術（RFA）は、特に既存の肝機能障害や凝固障害のある患者において、処置後の感染や出血と関連しています。

さらに、皮膚のリサーフェイシングやしわの減少に使用されるレーザーアブレーションデバイスは、時に表面的な火傷や瘢痕形成につながることがあり、患者の不満の原因となり、美容用途におけるこのような機器の評判を落としています。

特に心不整脈や特定の腫瘍に対するアブレーション療法は、必ずしも永久的な効果が得られるとは限らず、症状の再発につながることがあります。例えば、アブレーション治療を受けた心房細動患者は、数年以内に不整脈が再発し、再手術や代替治療が必要になることがあります。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • テクノロジー別
  • 用途別
  • エンドユーザー別
  • 地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • アブレーションデバイスにおける技術進歩の高まり
    • 抑制要因
      • 潜在的な副作用と合併症
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 アブレーションデバイス市場、テクノロジー別

  • 高周波アブレーション
  • マイクロ波アブレーション
  • 凍結療法
  • 超音波アブレーション
  • レーザー/光アブレーション
  • 電気アブレーション
  • その他

第6章 アブレーションデバイス市場、用途別

  • がん
  • 眼科
  • 心臓血管
  • 泌尿器科
  • 整形外科
  • 婦人科
  • 美容外科
  • 疼痛管理
  • その他

第7章 アブレーションデバイス市場、エンドユーザー別

  • 病院
  • 外科センター
  • 美容クリニック
  • 外来手術センター
  • その他

第8章 アブレーションデバイス市場、地域別、市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Boston Scientific Corporation
  • Medtronic plc
  • Johnson & Johnson
  • Olympus Corporation
  • Stryker Corporation
  • Hologic, Inc.
  • CONMED Corporation
  • Koninklijke Philips N.V.
  • CooperSurgical, Inc.

第11章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第12章 付録

目次
Product Code: MD861

The global ablation devices market reached US$ 6.2 billion in 2024 and is expected to reach US$ 14.1 billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033.

Ablation devices are specialized medical instruments used in various therapeutic procedures to remove, destroy, or treat abnormal or diseased tissue through targeted energy. These devices are often used in minimally invasive procedures, offering precise and controlled methods of treatment with minimal damage to surrounding healthy tissues. Ablation is typically performed using various forms of energy such as heat, cold, electricity, or light. Ablation devices play a critical role in modern medicine, providing patients with safer, more efficient, and less invasive treatment options for a variety of medical conditions.

The ablation devices market is experiencing significant growth, driven by advancements in ablation devices, rising product launches and an increasing preference for minimally invasive procedures. For instance, in October 2024, Abbott achieved new major milestones to support the company's growing suite of pulsed-field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt PFA System and the launch of the FOCALFLEX trial to assess the company's TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation.

Market Dynamics: Drivers & Restraints

Rising technological advancements in ablation devices

The rising technological advancements in ablation devices are significantly driving the growth of the Ablation Devices market and are expected to drive the market over the forecast period. Technological advancements, particularly in imaging and guidance systems, have greatly enhanced the precision of ablation procedures. These innovations are broadening the scope of applications, reducing procedure times, improving patient outcomes, and expanding access to minimally invasive options.

The integration of advanced electroanatomical mapping systems has revolutionized its use in cardiology, especially for treating atrial fibrillation. The ability to map the heart's electrical activity with precision has led to better success rates and lower recurrence of arrhythmias after treatment.

For instance, in October 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation (PFA) System.

Additionally, in October 2024, Medtronic plc announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density (HD) mapping and pulsed-field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter.

Robotic-assisted ablation systems are improving the accuracy and control of procedures. For instance, in December 2024, Stereotaxis Inc. and Chinese partner Shanghai Microport EP Medtech Co. Ltd. gained the National Medical Products Administration's approval of its Magbot magnetic navigation ablation catheter for use with Stereotaxis' robotic ablation system to treat drug-resistant cardiac arrhythmias in China.

Potential side effects and complications

Potential side effects and complications associated with ablation procedures are a significant challenge to the growth of the ablation devices market. These risks can deter patients and healthcare providers from adopting ablation technologies, limiting their widespread use. For instance, during radiofrequency or cryoablation for atrial fibrillation, there is a risk of causing esophageal injury or collateral damage to nearby nerves, such as the phrenic nerve, leading to complications like difficulty breathing.

Invasive procedures, such as catheter-based ablations, carry a risk of infection and bleeding at the insertion site. For instance, microwave ablation (MWA) or radiofrequency ablation (RFA) for liver tumors has been associated with post-procedural infections and bleeding, particularly in patients with pre-existing liver dysfunction or coagulopathies.

Additionally, laser ablation devices used for skin resurfacing or wrinkle reduction can sometimes lead to superficial burns or scarring, causing dissatisfaction among patients and tarnishing the reputation of such devices in cosmetic applications.

Ablation therapies, particularly for cardiac arrhythmias and certain tumors, may not always provide permanent results, leading to condition recurrence. For instance, atrial fibrillation patients treated with ablation may experience arrhythmia recurrence within a few years, requiring repeat procedures or alternative treatments.

Segment Analysis

The global ablation devices market is segmented based on technology, application, end-user and region.

Technology:

The radiofrequency ablation segment is expected to dominate the ablation devices market share

In cardiac ablation, radiofrequency ablation is most commonly used to treat atrial fibrillation (AF) and other arrhythmias by destroying or isolating the abnormal electrical pathways in the heart. The global prevalence of AF is increasing, leading to a growing demand for radiofrequency ablation devices. For instance, according to the National Institute of Health (NIH), the worldwide prevalence of atrial fibrillation is 37,574 million cases (0.51% of the worldwide population), increased by 33% during the last 20 years.

Radiofrequency ablation is also used in the treatment of chronic pain by targeting nerves that cause pain. It is especially used in conditions like osteoarthritis and back pain. This versatility in treating various pain conditions across multiple specialties has helped solidify radiofrequency ablation's market dominance. For instance, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain.

Advances in radiofrequency ablation technology, such as the development of more precise catheter designs, multi-electrode systems, and integrated mapping systems, have contributed to its increased efficiency and safety. For instance, in April 2024, a Minnesota-based medical technology company launched its OneRF Ablation System, which creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures. According to a release from NeuroOne Medical Technologies, this system is the company's first device with a therapeutic indication. The thin-film, stereoelectroencephalopathy-guided radio frequency system is capable of both recording electrical activity and ablating nervous tissue while offering temperature control during surgical procedures.

Geographical Analysis

North America is expected to hold a significant position in the ablation devices market share

North America, particularly the United States, is a global leader in the development and adoption of cutting-edge medical technologies. Many of the world's leading companies in the ablation devices market are based in North America, including Medtronic, Boston Scientific and Johnson & Johnson, which are pioneers in radiofrequency, cryoablation and microwave ablation technologies. The region continues to invest heavily in research and development, driving innovation in ablation devices.

For instance, in November 2024, Johnson & Johnson MedTech announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform for the treatment of drug-refractory paroxysmal Atrial Fibrillation (AFib). The VARIPULSE Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy.

The U.S. Food and Drug Administration (FDA) plays a critical role in the regulatory approval of medical devices, and its rigorous yet supportive framework for innovative technologies has helped speed up the availability of new ablation devices. Devices such as Medtronic's Arctic Front Cryoballoon and Biosense Webster's ThermoCool SmartTouch Catheter have received FDA approval, ensuring that North America remains at the forefront of adopting the latest and most advanced ablation technologies. This rising FDA approvals of advanced ablation devices is driving the market in the region.

For instance, in August 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced that several products in its market-leading cardiac ablation portfolio have received approval for a zero fluoroscopy workflow from the U.S. Food and Drug Administration (FDA). The products that can be used in this workflow include: THERMOCOOL SMARTTOUCH SF catheter, the most commonly used ablation catheter in the world for RF ablation, THERMOCOOL SMARTTOUCH Catheter, CARTO VIZIGO Bi-Directional Guiding Sheath, PENTARAY NAV ECO High-Density Mapping Catheter, DECANAV Mapping Catheters, and Webster CS Catheter.

Asia-Pacific is growing at the fastest pace in the ablation devices market

The prevalence of chronic conditions, such as cardiovascular diseases (CVDs), cancer and diabetes, is rapidly increasing in the Asia-Pacific region, fueling the demand for ablation therapies. Conditions like atrial fibrillation and liver cancer are becoming more common, and ablation is a preferred treatment for these diseases due to its minimally invasive nature.

For instance, as the incidence of cancer increases, particularly liver, lung and kidney cancers, the need for tumor ablation devices is also rising. The World Health Organization (WHO) forecasts that cancer cases in India will rise by 40% by 2030, further driving demand for ablation therapies.

The Asia Pacific region is seeing significant improvements in healthcare infrastructure, especially in countries like China, India, Japan, South Korea, and Australia. These countries are investing heavily in modern healthcare technologies, leading to increased adoption of advanced medical devices, including ablation technologies. Many hospitals and healthcare facilities are expanding their capacity to provide cutting-edge treatments, driving the demand for ablation devices.

For instance, in September 2024, Kauvery Hospital launched Fluoroless Ablation for Atrial Fibrillation, setting a new benchmark in the treatment of one of the most common heart rhythm disorders. Kauvery Hospital continues to push the boundaries of medical innovation to ensure that patients receive the most effective and minimally invasive treatments available.

Competitive Landscape

The major global players in the ablation devices market include Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Johnson & Johnson, Olympus Corporation, Stryker Corporation, Hologic, Inc., CONMED Corporation, Koninklijke Philips N.V., CooperSurgical, Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global ablation devices market report delivers a detailed analysis with 62 key tables, more than 64 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Technology
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Ablation Devices
    • 3.1.2. Restraints
      • 3.1.2.1. Potential Side Effects and Complications
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Ablation Devices Market, By Technology

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 5.1.2. Market Attractiveness Index, By Technology
  • 5.2. Radiofrequency Ablation*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Microwave Ablation
  • 5.4. Cryoablation
  • 5.5. Ultrasound Ablation
  • 5.6. Laser/Light Ablation
  • 5.7. Electrical Ablation
  • 5.8. Others

6. Ablation Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Ophthalmology
  • 6.4. Cardiovascular
  • 6.5. Urology
  • 6.6. Orthopedic
  • 6.7. Gynecology
  • 6.8. Aesthetic/Cosmetic Surgery
  • 6.9. Pain Management
  • 6.10. Others

7. Ablation Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Surgical Centers
  • 7.4. Aesthetic Clinics
  • 7.5. Ambulatory Surgical Centers
  • 7.6. Others

8. Ablation Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott Laboratories*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Boston Scientific Corporation
  • 10.3. Medtronic plc
  • 10.4. Johnson & Johnson
  • 10.5. Olympus Corporation
  • 10.6. Stryker Corporation
  • 10.7. Hologic, Inc.
  • 10.8. CONMED Corporation
  • 10.9. Koninklijke Philips N.V.
  • 10.10. CooperSurgical, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us